What is Alto Neuroscience's current debt?

Alto Neuroscience (ANRO) reported current debt of $2.14M in Q1 2026.

What does current debt mean?

The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Alto Neuroscience ANRO Current Debt

Current Debt at other companies

MeiraGTx Holdings plcMGTX

$39K—

Axsome TherapeuticsAXSM

$70M—

MedtronicMDT

$1.79B-37.8%

IAR

Integra LifeSciencesIART

$53.28M+37.5%

RevvityRVTY

$575.83M+237,847%

AlkermesALKS

——

Other financials

Income statement

See full

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Balance sheet

See full

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Cash flow

See full

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Valuation

See full

Market cap$874.19M+1,335%

Enterprise value$630.81M-940%

Returns & leverage

See full

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alto Neuroscience's current debt?: Alto Neuroscience (ANRO) reported current debt of $2.14M in Q1 2026.
What does current debt mean?: The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.